Bajaj Healthcare Limited’s shares rose by 0.69 per cent to ₹451.85, hitting a 52-week high of ₹466.30 on the BSE today. Following the announcement that the company has secured new CDMO contracts with UK- and EU-based companies for 15 additional active pharmaceutical ingredients (APIs), this development builds on a similar deal for 15 molecules signed in February 2024.

According to its report, the new CDMO pipeline comprises a mix of off-patent generic APIs and that are still under patent.

• Also read: Adani Power seeks lifeline for troubled power plant amid Bangladesh payment delays

Anil Jain, Managing Director of Bajaj Healthcare, “We are delighted to announce this development, which underscores the growing capabilities we are building in cost-effective synthesis, advanced R&D, and expanded manufacturing”. 

Furthermore,with the TGA approval, Bajaj Healthcare is now positioned to enter into CDMO deals with clients in Australia, New Zealand, and South Africa.